Skip to main content

Point-of-Care Dx Firm iAssay, DDTD Partner on COVID-19 Testing

NEW YORK – Point-of-care diagnostics company iAssay said this week it and DDTD (Drugs &n Diagnostics for Tropical Diseases) have signed a memorandum of understanding to facilitate the use of the iAssay instrument to read, interpret, and transmit test images and accelerate the reporting of test results to physicians.

According to iAssay, the MOU will allow organizations to provide DDTD's COVID-19 serology tests with automatic, digitized reads that can be transmitted simultaneously and securely using iAssay's SimpleCloud Amazon Web Services portal to health records. iAssay noted that in the US Department of Health and Human Services mandates all COVID-19 test results be reported to the agency or risk getting fined. The SimpleTest, it added, sends test results automatically, in compliance with HHS rules.

The San Diego-based company also said it plans to evaluate the test incorporating DDTD's COVID-19 test strip into iAssay's instrument in support of a submission to the US Food and Drug Administration for possible Emergency Use Authorization. DDTD's test strip detects IgG antibodies against SARS-CoV-2, and the iAssay instrument interprets test results, an iAssay spokesperson said.

Financial and other terms of the partnership were not disclosed.